Latest News

Around the Helix: Cell and Gene Therapy Company Updates – November 6, 2024
Around the Helix: Cell and Gene Therapy Company Updates – November 6, 2024

November 6th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

HuidaGene Therapeutics’ CRISPR/Cas13 RNA-Editing Therapy HG202 Gets Greenlight for US Trial in Age-Related Macular Degeneration
HuidaGene Therapeutics’ CRISPR/Cas13 RNA-Editing Therapy HG202 Gets Greenlight for US Trial in Age-Related Macular Degeneration

November 6th 2024

Sandi See Tai, MD, chief development officer at Lexeo
Gene Therapy for APOE4 Homozygous Alzheimer Disease

November 6th 2024

 Capsida Biotherapeutics' CAP-003 Displays Properties of Disease-Modification in Preclinical Parkinson Disease Research
Capsida Biotherapeutics' CAP-003 Displays Properties of Disease-Modification in Preclinical Parkinson Disease Research

November 5th 2024

Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
Noninflammatory Neurotoxicity Events in Patients Receiving CAR-T

November 5th 2024

Video Interviews

Conference Coverage

View All
Sandi See Tai, MD, chief development officer at Lexeo
Gene Therapy for APOE4 Homozygous Alzheimer Disease

November 6th 2024

 Capsida Biotherapeutics' CAP-003 Displays Properties of Disease-Modification in Preclinical Parkinson Disease Research
Capsida Biotherapeutics' CAP-003 Displays Properties of Disease-Modification in Preclinical Parkinson Disease Research

November 5th 2024

Lexeo Therapeutics' Gene Therapy LX1001 Increases APOE2 Expression in Patients With Alzheimer Disease
Lexeo Therapeutics' Gene Therapy LX1001 Increases APOE2 Expression in Patients With Alzheimer Disease

November 4th 2024

R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease

October 31st 2024

All News

© 2024 MJH Life Sciences

All rights reserved.